Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Postnatal depression which persists beyond six months after birth and is severe, increases the risk of children exhibiting behavioural problems, achieving lower GCSE mathematics grades at 16 years and having depression at 18 years of age.

Image courtesy of Shutterstock

Postnatal depression which is persistent (whether moderate or severe) increases mothers’ risk of continuing to experience depressive symptoms beyond the postnatal year, with high levels found up until 11 years after childbirth.

Available research suggests that postnatal depression is associated with increased risks to children’s development affecting a range of domains. The effects are variable with some evidence suggesting that brief episodes, while distressing to the mother, may not impact negatively on children’s development. However, episodes of depression which persist for six months or more in duration may increase the risk for children. Identifying women at most risk is important both for women’s mental health and children’s development. The authors investigated whether depression has a similar impact when it is, or is not, persistent at either moderate or severe levels. Researchers from the Universities of Oxford, Bristol, Reading and UCLA in a new paper in JAMA Psychiatry tracked changes in mothers’ depressive symptoms following the postnatal year and differences in children’s development when postnatal depression was, or was not, persistent.

Find out more (University of Oxford website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.